Line 91: | Line 91: | ||
<section id="third" class="step"> | <section id="third" class="step"> | ||
<div> | <div> | ||
− | CATE is administered intravenously, travels through the blood and colonizes tumors | + | CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have gathered at the tumor, they make themselves visible and prepare a |
+ | payload. A doctor can then control the site with an MRI and activate release of the cancer-killing payload. | ||
<br> | <br> | ||
<br> | <br> | ||
− | + | <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Treatment</a> | |
− | + | ||
− | + | ||
− | <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more"> | + | |
</div> | </div> | ||
Revision as of 09:46, 19 October 2017
We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one
living cancer therapeutic with an integrated two-step safety mechanism. That's why we created CATE: Cancer-Targeting E. coli.
A living cure to a living disease.
Background
It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.
Description
Treatment